16-Dehydro-3β-[(t-Butyl)dimethylsiloxy]androst-5-ene-7-one Trifluoromethanesulfonate is an intermediate in synthesizing 7-Ketoabiraterone Acetate (K170980), a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent prostate cancer.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.